Of course, in addition to PD-L1 and TIL, potential biomarkers such as tumor mutational burden (TMB), microsatellite instability (MSI) and immune-related genes, have also shown themselves in breast cancer immunotherapy. This evidence concerns the gene CD274 and breast cancer.